

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

VOLUNTARY ANNOUNCEMENT HEALTHCARE SERVICES BUSINESS COOPERATION AGREEMENT

This announcement is made by China Biotech Services Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 18 January 2023 (after trading hours), Precision Health Care Services Limited (“**Precision Health Care**”), an indirect non-wholly-owned subsidiary of the Company, entered into a business cooperation agreement (the “**Business Cooperation Agreement**”) with Shenzhen Ganlan Health Information Co. Ltd.* (深圳橄欖健康信息有限公司) (“**SGHI**”), pursuant to which the parties agreed to cooperate to promote Precision Health Care’s Healthcare Services (as defined below) in the People’s Republic of China (the “**PRC**”).

THE BUSINESS COOPERATION AGREEMENT

The principal terms of the Business Cooperation Agreement are set out below:

- Date:** 18 January 2023
- Parties:** (i) Precision Health Care; and
(ii) SGHI.

SGHI is a company established in the PRC with limited liability. As at the date of this announcement, SGHI is principally engaged in medical information consulting and health management consulting services. To the best of the Directors' knowledge and information, having made all reasonable enquiries, SGHI and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "**GEM Listing Rules**")).

Subject matter:

Pursuant to the Business Cooperation Agreement, the parties agree to cooperate in respect of Precision Health Care's diagnostic and health check services (the "**Healthcare Services**") in the following manner:

- (1) SGHI agrees to act as Precision Health Care's cooperative agent to promote Precision Health Care's Healthcare Services in the PRC through the provision of information consulting and appointment referral services;
- (2) Precision Health Care authorises SGHI to act as a non-exclusive agent of its Healthcare Services in the PRC; and
- (3) SGHI agrees to introduce Precision Health Care's Healthcare Services to its customers (the "**Customers**") in exchange for a fee. For bookings made by SGHI on behalf of the Customers to Precision Health Care following successful referrals by SGHI for Precision Health Care's prescribed scope of services, Precision Health Care would provide the said services to the Customers at its three locations of testing centres in Hong Kong and pay agency fees to SGHI in accordance with the terms of the Business Cooperation Agreement; and for any additional bookings made directly by the Customers to Precision Health Care for services outside the prescribed scope, Precision Health Care agrees to pay a commission to SGHI.

Term: The Business Cooperation Agreement has a term commencing from 18 January 2023 and ending on 31 December 2023. If neither party has given a written notice to the other party at least thirty (30) days prior to such expiry date to terminate the Business Cooperation Agreement, the term will be automatically extended to one (1) year after the original expiry date or the end of the service period in respect of the Healthcare Services provided to the Customers referred to Precision Health Care by SGHI, whichever is later.

REASONS FOR AND BENEFITS OF ENTERING INTO THE BUSINESS COOPERATION AGREEMENT

The provision of medical laboratory testing services and health check services in Hong Kong is among the core and principal business activities of the Group. The Company has been providing a broad spectrum of such services with a long operating history through its various operating subsidiaries, including Precision Health Care. As the Group continues to establish its presence in various biotechnology sectors in the PRC, it is able to leverage its connections within the PRC to expand the geographical reach of one of the Group's oldest business segments.

The Board believes that the formation of the cooperative partnership with SGHI through the Business Cooperation Agreement will be beneficial to the long-term growth of the Group's core business in the provision of Healthcare Services by drastically expanding its customer base geographically and in turn maximise return to the Company and its shareholders in the long run.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 19 January 2023

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Ms. Chui Hoi Yam; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.

** for identification purpose only*